anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Electroceuticals, through the selective modulation of peripheral nerves near target organs, are promising for treating refractory diseases. However, the small sizes and the delicate nature of these nerves present challenges in simplifying the fixation and stabilizing the electrical-coupling interface for neural electrodes. Herein, we construct a robust neural interface for fine peripheral nerves using an injectable bio-adhesive hydrogel bioelectronics. By incorporating a multifunctional molecular regulator during network formation, we optimize the injectability and conductivity of the hydrogel through fine-tuning reaction kinetics and multi-scale interactions within the conductive network. Meanwhile, the mechanical and electrical stability of the hydrogel is achieved without compromising its injectability. Minimal tissue damage along with low and stable impedance of the injectable neural interface enables chronic vagus neuromodulation for myocardial infarction therapy in the male rat model. Our highly-stable, injectable, conductive hydrogel bioelectronics are readily available to target challenging anatomical locations, paving the way for future precision bioelectronic medicine.
BACKGROUND: Due to its unique advantages over radical cystectomy (RC), trimodality therapy (TMT) is increasingly being utilized by patients diagnosed with muscle-invasive bladder cancer (MIBC) who are not suitable for or refuse RC. However, achieving a satisfactory oncological outcome with TMT requires strict patient selection criteria, and the comparative oncological outcomes of TMT versus RC remain controversial.
METHODS: Patients diagnosed with non-metastatic MIBC who underwent TMT or RC were identified from the SEER database during 2004-2015. Before one-to-one propensity score matching (PSM), logistic regression was utilized to identify predictors of TMT. After matching, K-M curves were generated to estimate cancer-specific survival (CSS) and overall survival (OS) with log-rank to test the significance. Finally, we conducted univariate and multivariate Cox analyses to identify independent prognostic factors for CSS and OS.
RESULTS: The RC and TMT groups included 5812 and 1260 patients, respectively, and the TMT patients were significantly older than the RC patients. Patients with advanced age, separated, divorced, or widowed (SDW) or unmarried marital status (married as reference), and larger tumor size (< 40 mm as reference) were more likely to be treated with TMT. After PSM, TMT was found to be associated with worse CSS and OS, and it was identified as an independent risk factor for both CSS and OS.
CONCLUSION: MIBC patients may not be carefully evaluated prior to TMT, and some non-ideal candidates underwent TMT. TMT resulted in worse CSS and OS in the contemporary era, but these results may be biased. Strict TMT candidate criteria and TMT treatment modality should be required.
The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., "urge-surfing"). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430).
In this study, pilates exercise will be applied for 8 weeks, 2 days a week. Participants will be evaluated at the beginning of the study, at the end of the first session and after 8 weeks.
PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
Premature infants born at \< 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of \[5,5,5-2H3\]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
The primary aim of this study was to determine if occupational exposure to whole-body vibration (WBV) was associated with reporting neck pain. A cross-sectional study was conducted on a sample of the general population living in northern Sweden, aged 24-76 years. Data was retrieved through a digital survey that collected subjectively reported information on exposure to WBV and biomechanical exposures as well as neck pain. The study included 5,017 participants (response rate 44%). Neck pain was reported by 269 men (11.8%) and 536 women (20.2%). There was a statistically significant association between reporting occupational exposure to WBV half the time or more (adjusted OR 1.91; 95% CI 1.22-3.00) and reporting neck pain. In gender-stratified analyses, the same pattern was observed in men, while there were too few women to determine any association. We conclude that occupational exposure to whole-body vibration was associated with neck pain in men.Practitioner summary: This cross-sectional, survey-based study investigated associations between self-reported occupational whole-body vibration and neck pain. It showed significant associations between frequent exposure to whole-body vibration and neck pain among men but not women. In occupational health care settings, whole-body vibration could be considered as a possible risk factor for neck pain.
OBJECTIVE: In early-stage endometrial cancer, aggressive histologic types (grade 3 endometrioid, serous, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types) are associated with an increased risk of distant metastases and worse survival. However, the optimal adjuvant treatment for these patients remains controversial. The present study investigated the outcomes of different adjuvant treatments in patients with 2023 FIGO stage IIC endometrial cancer.
METHODS: We retrospectively identified patients with 2023 FIGO stage IIC endometrial cancer who underwent surgery followed by either adjuvant treatment or observation from 2000 to 2020 at two tertiary centers in Korea and Taiwan. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using Kaplan-Meier estimates and Cox proportional-hazards models. We also analyzed recurrence patterns after different adjuvant treatments.
RESULTS: A total of 272 patients were identified; 204 received adjuvant treatment postoperatively, whereas 68 only underwent observation. Adjuvant treatment was not associated with improved RFS or OS. Non-endometrioid histologic types (p=0.003) and presence of lymphovascular space invasion (LVSI, p=0.002) were associated with worse RFS, whereas only non-endometrioid histologic types impacted OS (p=0.004). In subgroup analyses, adjuvant treatment improved OS in patients with LVSI (p=0.020) and in patients with both LVSI and grade 3 endometrioid histologic type (p=0.007). We found no difference in locoregional and distant recurrence between patients undergoing adjuvant treatment or observation.
CONCLUSION: In this study, the addition of adjuvant treatment was associated with an OS benefit for patients with LVSI, especially those with grade 3 endometrioid tumors.
BACKGROUND: To evaluate the association between handgrip strength (HGS) weakness and asymmetry with incident hip fracture among older Chinese adults.
METHODS: Data was obtained from the 2011 and 2015 waves of the China Health and Retirement Longitudinal Study (CHARLS). HGS weakness was defined as maximal HGS 〈 28 kg in men and < 18 kg in women. HGS asymmetry was defined as the HGS ratio < 0.9 or 〉 1.1. Participants were categorized into normal HGS, weakness only, asymmetry only, and both weakness and asymmetry. Given the sex differences in HGS, the association between HGS weakness and asymmetry was analyzed by sex using the multivariable logistic regression models.
RESULTS: A total of 4789 participants aged ≥ 60 years old without hip fracture at baseline were included in the final analysis. Over the four-year follow-up, there were 152 (3.17 %) participants having incident hip fractures, of which 69 (2.90 %) were men and 83 (3.45 %) were women. Compared to the normal group, men with both weakness and asymmetry had a significantly higher risk of incident hip fracture in the fully adjusted model (adjusted odds ratio (OR): 2.31, 95 % confidence interval (CI):1.17-4.52). There was no significant association between HGS asymmetry and weakness with hip fracture in women.
CONCLUSIONS: Our findings indicated that among the Chinese population, men with both HGS weakness and asymmetry were associated with increased odds of hip fracture, while no significant association was observed in women.
The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
1412204 Free-flowing choline chloride BADISCHE ANILIN- & SODA-FABRIK AG 27 Feb 1973 [29 Feb 1972] 9484/73 Heading C2C Free-flowing choline chloride powder containing at least 50% by weight of choline chloride based on the total weight of the composition, the remainder being substantially silicic acid with or without water or solvent, and which has a flow grading of 1, 2 or 3 i.e. it flows freely through a hole of diameter 2.5 mm., 5 mm. or 8 mm. is prepared by (a) mixing an aqueous solution of choline chloride with at least 2% by weight of hydrophilic silicic acid and at least 3% by weight of hydrophobized silicic acid based on choline chloride, the mixing being terminated before the stage is reached at which silicic acid no longer rises to the surface of the mixture within 15 seconds when agitation is stopped whilst the liquid mixture remains slightly mobile (b) spray-drying the mixture to form a powder, separating the spray-dried powder from the carrier gas stream, and (c) cooling the powder whilst maintaining it in constant motion. The aqueous solution preferably contains 50-80% by weight of choline chloride and at least 3 % by weight of hydrophilic silicic acid and/or at least 4 % by weight of hydrophobized silicic acid, each type representing 30-70% of the total silicic acid. The powder obtained preferably has a residual moisture content of 0.5-5% by weight. The hydrophobized silicic acid is obtained by treating silicic acid with a chloroalkyl silane.
PURPOSE:To enable the manufacture of a specified monoclonal antibody, by using a tissue type plasminogen activator sampled from a calture of cells derived from a normal human tissue. CONSTITUTION:A monoclonal antibody having such specificity as give by the formula can be manufactured with respect to t-PA sampled from a culture of cells derived from a normal human tissue. The monoclonal antibody obtained has a nature of being unable to bond to a fibrinolysis activity developed part and a fibrin affinity part of t-PA. But this method provides a monoclonal antibody which is reactive to a different antigen determinant part. To achieve this, desired miscellaneous cells are cultivated in an appropriate calture which comprises a RPMI1640 or the like containing about 10% of bovine embryonic serum and then, the monoclonal antibody can be obtained from the supernatant of the culture. The refining of an antihuman tissue type plasminogen activator monoclonal antibody from abdominal dropsy is conducted in accordance with the ordinary recovery method of antibodys from serum. Thus, a very high-purity t-PA can be obtained at a high recovery rate.
Participants will be randomized to receive matching placebo in any of the 11 cohorts. In each dosing cohort, 2 participants will receive a single dose of matching placebo.
The invention provides an ilaprazole enteric capsule and a preparation method thereof. The ilaprazole enteric capsule comprises enteric pellets and capsule auxiliary materials accepted in pharmacy, wherein the enteric pellets include pellet cores, isolation layers and enteric coating layers, and the pellet cores comprise ilaprazole or salt and stabilizing agents accepted in pharmacy. The ilaprazole enteric capsule has good acid resistance, is favorable for human health and safety due to the fact that prescription doesn't contain obstacle materials of anti-acid agents, surface active agents, organic solvents, hydrophobic materials or the like. After the capsule is taken, the pellets can be widely and evenly distributed in intestinal tracts. Dosage is dumped in scatter mode, so that distribution area of medicine on the surface of the intestinal tracts is enlarged, irritation of the medicine on the intestinal tracts is reduced or eliminated, and biological utilization rate of the medicine is improved. When the capsule is taken, content in the capsule can be poured out to be directly taken. Thus, the capsule is also suitable for patients with difficulties in swallowing and infants.
The invention discloses compound glycyrrhizin tablets. The compound glycyrrhizin tablets are prepared from a main drug raw material comprising glycyrrhizic acid ammonium salt, glycine and DL-methionine and an auxiliary material comprising a filling agent and a disintegrating agent. The mass ratio of the main drug raw material to the auxiliary material is 1:(1.7-2.8). The filling agent is prepared by evenly mixing mannitol and starch in a mass ratio of 2:1, and the disintegrating agent is xanthan gum. The invention further discloses a preparation method of the compound glycyrrhizin tablets. The method sequentially comprises the steps of grinding, screening, mixing and tabletting, and then the compound glycyrrhizin tablets are prepared. Due to mannitol in the auxiliary material, the situation that the drug quality is unqualified caused by moisture absorption of glycyrrhizic glycoside can be avoided, and the sweetness of mannitol can mask the bitterness of the tablets; by matching with the starch and xanthan gum in a certain ratio, the raw materials of the tablets are good in fluidity and pressing-ability; the technology is simple, energy conservation and environment protection are achieved, and the production cost is low.
A method for rejuvenation of the skin in the face and the neck comprises the clinical examination, the assessment of the state of skin, the diagnosis and the treatment. The mixture containing 25-40 mL of soft petroleum ointment, 0.5-10 mL of the almond oil, 3-20 mL of the chamomile infusion, 0.5-4.0 hyaluronic acid and 1.0-5.0 of the sea salt is prepared and mixed thoroughly to homogeneity. The mixture is applied on the skin in the face and the neck by the slight massaging movements for 40-45 minutes in 2 hours preceding the sleep. The remaining mixture is then washed out with warm water with the cotton swab. The applications are provided for 2 months with 20-day interval. The results are assessed visually.
PURPOSE: A composition containing astaxanthin for protecting neural progenitor cells and preventing neurodegenerative diseases is provided to suppress apoptosis of neural progenitor cells and induce proliferation of the cells. CONSTITUTION: A composition for protecting neural progenitor cells contains astaxanthin as an active ingredient. A composition for preventing neurodegenerative diseases contains astaxanthin as an active ingredient. The neurodegenerative diseases are Alzheimer's disease, Parkinson's disease, spinal cord injury, or ischemia. The composition is manufactured in the form of oral formulation, parenteral formulation, or health food. The oral formulation is granules, tablets, capsules, and liquids.
The objective of this study is to determine the relative gentleness of a new medical tape. A three-prong multidimensional evaluation consisting of expert grader, subject discomfort assessment, and laboratory assessments was used. One pre-study visit took place up to 7 days prior to the start of the study. The study was conducted over two days with one tape sample applied and removed. Assessments were taken on the final day. This was to mimic a normal tape application in health care practice.
A majority of cervical carcinomas are caused by an uncontrolled, persistent infection with high risk Human Papilloma Virus (HPV). ISA101/ISA101b is a novel therapeutic synthetic long peptide (SLP) vaccine targeting HPV16 which is being developed and has shown efficacy in patients with high-grade premalignant vulvar lesions caused by HPV with only minor toxicity. For most advanced cancers, chemotherapy remains the treatment modality of choice but has been considered to be immunosuppressive. However, accumulating evidence indicates that many modalities of conventional chemotherapy not only are less immunosuppressive than previously thought but in fact can exert favorable effects on the tumor micro-environment by interfering with suppressive immune cells and by stimulating the release of immune activating molecules by tumor cells. Thus chemotherapy may enhance tumor-specific immunity and synergize with cancer immunotherapy. Addition of pegylated interferon alpha (IFNα) two-b (IIb) to vaccination might even further improve the immune response. This multicenter, open label, non-randomized Phase I/II study will be performed to assess the safety and tolerability of the ISA101/ISA101b vaccine, and the immune modulating effects of ISA101 (with or without pegylated IFNα)/ISA101b when combined with carboplatin and paclitaxel, with or without bevacizumab.
Cognitive decline is inevitable with age, and due to the lack of well-established pharmacotherapies for neurodegenerative disorders, dietary supplements have become important alternatives to ameliorate brain deterioration. Hydrolyzed chicken meat extract (HCE) and its bioactive components were previously found to improve neuroinflammation and cognitive decline by regulating microglia polarization. However, the effects and mechanisms of these bioactives on neurons remain unclear. Here, the most potent bioactive component on neural function in HCE was screened out, and the detailed mechanism was clarified through in vivo and in vitro experiments. We found that HCE, cyclo(Val-Pro), cyclo(Phe-Phe), cyclo(His-Pro), cyclo(Leu-Lys), and arginine exerted stronger anti-inflammatory and antioxidant effects among the 12 bioactives in amyloid β (Aβ)-treated HT-22 cells. Further transcriptome sequencing and polymerase chain reaction (PCR) array analysis showed that these bioactives participated in different signaling pathways, and cyclo(Val-Pro) was identified as the most potent cyclic dipeptide. In addition, the antiapoptotic and neuroprotective effect of cyclo(Val-Pro) was partly regulated by the activation of PI3K/AKT and AMPK pathways, and the inhibition of these pathways abolished the effect of cyclo(Val-Pro). Moreover, cyclo(Val-Pro) enhanced cognitive function and neurogenesis and alleviated neuroinflammation and oxidative stress in middle-aged mice, with an effect similar to HCE. Hippocampal transcriptome analysis further revealed that HCE and cyclo(Val-Pro) significantly enriched the neuroactive ligand-receptor interaction pathway, verified by enhanced neurotransmitter levels and upregulated neurotransmitter receptor-related gene expression. Therefore, the mechanism of cyclo(Val-Pro) on neural function might be associated with PI3K/AKT and AMPK pathway-mediated antiapoptotic effect and neurogenesis and the activation of the neurotransmitter-receptor pathway.
A dental prophylaxis tablet is disclosed containing abrasives and anticaries compounds. The tablet is hard enough to withstand normal storage and handling. The tablet also contains dispersing and wetting agents so that it may be readily constituted into a dental prophylaxis paste by the addition of water and may contain sweeteners and flavors. A typical tablet is approximately one gram in weight and has hardness of about 3.5 to 4.0 kilograms (Pfizer tester). A typical tablet can be hydrated in approximately 60 seconds with the addition of water to form a prophylaxis paste. A typical formulation is: feldspar 61%, Cabosil (TM) 1%, Instant ClearJel (TM) 5%, Sta Rx 1500 (TM) 25%, sodium saccharin 0.5%, sodium citrate 0.5%, stannous fluoride 5%, Stearowet-C (TM) 0.5% and flavors 1%.
OBJECTIVE: The clinical effects of artificial dermis in treating skin and soft tissue defects accompanied by bone or tendon exposure were assessed.
APPROACH: A retrospective analysis was conducted on the clinical data of 45 cases of skin and soft tissue defects accompanied by bone or tendon exposure admitted to the trauma surgery department of Fujian Provincial Hospital between February 2018 and August 2020. They were divided into the artificial dermis and control groups. The wound was assessed using the Vancouver Scar Scale (mVSS), and the postoperative visual analogue scale (VAS) scores were recorded at 3, 6, 9, and 12 months after surgery. At the 12-month after surgery, skin sensation recovery was evaluated using the criteria of the British Medical Research Council (BMRC).
RESULTS: The cases included 26 males and 19 females, aged 50 to 85 years. All patients were followed up for an average of 13.8 months (range: 12-18 months). Compared with controls, the wound healing time of the observation group was longer (35.8 ± 10.6 vs. 28.5 ± 4.8, P = 0.007), without significant differences for the number of operations and length of hospitalization. The mVSS scores were not different between groups (Pgroup = 0.294), but the scores decreased with time (Ptime < 0.001), and the group×time interaction was significant (Pinteraction < 0.001). Similarly, the VAS scores were not different between groups (Pgroup = 0.667), but the scores decreased with time (Ptime < 0.001); the group×time interaction was not significant (Pinteraction = 0.274). At the 12-month mark following the operation, in the artificial dermis group, the MCRR score was S3+ in 23 patients, while it ranged from S0 to S3 in two patients; in the control group, S3+ was observed in 17 patients, and S0-S3 in three (P = 0.815).
CONCLUSION: Artificial dermis treatment is considered a safe and effective alternative therapy for patients with skin and soft tissue defects accompanied by bone or tendon exposure who cannot tolerate or are unwilling to undergo autologous skin flap transplantation. It offers the advantages of minimal donor site trauma, simplicity in operation, and favorable postoperative functional recovery.
Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.